11/11
01:23 pm
imnn
Imunon, Inc. (NASDAQ: IMNN) had its price target lowered by analysts at HC Wainwright from $14.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
Imunon, Inc. (NASDAQ: IMNN) had its price target lowered by analysts at HC Wainwright from $14.00 to $12.00. They now have a "buy" rating on the stock.
11/8
02:37 am
imnn
Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ... [Yahoo! Finance]
Medium
Report
Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ... [Yahoo! Finance]
11/7
10:00 am
imnn
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
High
Report
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
11/7
08:05 am
imnn
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates
High
Report
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/31
08:30 am
imnn
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
Medium
Report
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
10/30
09:05 am
imnn
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting
Low
Report
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting
10/8
08:46 am
imnn
Imunon reports inducement grant under NASDAQ listing rule [Yahoo! Finance]
Low
Report
Imunon reports inducement grant under NASDAQ listing rule [Yahoo! Finance]
10/7
08:05 am
imnn
IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
9/25
07:39 am
imnn
Imunon, Inc. (NASDAQ: IMNN) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Low
Report
Imunon, Inc. (NASDAQ: IMNN) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
9/9
04:09 pm
imnn
UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management [Yahoo! Finance]
Low
Report
UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management [Yahoo! Finance]
9/9
04:06 pm
imnn
UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
Medium
Report
UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
9/9
08:30 am
imnn
IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
Low
Report
IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
8/28
08:30 am
imnn
IMUNON to Host R&D Day on September 18th
Medium
Report
IMUNON to Host R&D Day on September 18th